15:19 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Gastrointestinal cancer Cell culture and mouse studies identified a quinazoline-based compound that could help treat c-Kit- and PDGFR-mutant gastrointestinal stromal tumors (GISTs). Chemical synthesis of phenoxyquinazoline- and quinolone-based PDGFRA inhibitors followed by testing in...
18:20 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Ascentage hops in Hong Kong IPO queue

Ascentage Pharma Group International (Suzhou, China) proposed Aug. 20 to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by BofA Merrill Lynch and Citi. The biotech's pipeline comprises seven clinical...
19:48 , Aug 23, 2018 |  BC Extra  |  Tools & Techniques

Computational tool prospectively predicts resistance to cancer drugs

An Institute of Cancer Research team has developed a computational prediction tool that can predict which resistant mutations will develop in response to cancer drugs before a patient takes the drug. The results suggest the...
19:47 , Aug 20, 2018 |  BC Extra  |  Financial News

Ascentage hops in Hong Kong IPO queue

Ascentage Pharma Group International (Suzhou, China) proposed Monday to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by BofA Merrill Lynch and Citi. The biotech's pipeline comprises seven clinical candidates...
16:42 , Jul 20, 2018 |  BC Week In Review  |  Company News

Novartis halts price increases, reports 2Q earnings

Novartis AG (NYSE:NVS; SIX:NOVN) announced on July 18 that it will suspend for the rest of the year price increases in the U.S. The pharma made the announcement in conjunction with the release of its...
19:59 , Jul 18, 2018 |  BC Extra  |  Company News

Novartis halts price increases, reports 2Q earnings

Novartis AG (NYSE:NVS; SIX:NOVN) announced Wednesday that it will suspend for the rest of the year price increases in the U.S. The pharma made the announcement in conjunction with the release of its 2Q18 earnings....
18:21 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer, sarcoma Cell culture studies suggest inhibiting IFT88 or SCLT1 could help treat kinase inhibitor-resistant lung cancer and rhabdomyosarcoma. In a human EGFR inhibitor-resistant non-small cell lung cancer (NSCLC) cell line, the EGFR...
23:00 , Jun 7, 2018 |  BC Extra  |  Preclinical News

Targeting tumor cilia could reverse resistance to kinase inhibitors

A...
23:20 , Mar 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer; inflammation

INDICATION: Colorectal cancer; asthma Mouse and cell culture studies identified a RIPK2-inhibiting analog of Iclusig ponatinib that could help treat colorectal cancer and asthma....
00:00 , Jan 18, 2018 |  BioCentury  |  Emerging Company Profile

Computing brain entry

1st Biotherapeutics Inc. aims to develop a pipeline of first- or best-in-class molecules for CNS diseases by using computational tools to achieve better blood-brain barrier penetration and PK properties than marketed drugs against the same...